Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · Real-Time Price · USD
54.10
+4.42 (8.90%)
At close: Oct 17, 2025, 4:00 PM EDT
54.25
+0.15 (0.28%)
After-hours: Oct 17, 2025, 7:48 PM EDT
Revolution Medicines Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
534
Market Cap
10.11B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 11.58M | -23.80M | -67.27% |
| Dec 31, 2022 | 35.38M | 5.99M | 20.38% |
| Dec 31, 2021 | 29.39M | -13.59M | -31.62% |
| Dec 31, 2020 | 42.98M | -7.06M | -14.10% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
RVMD News
- 1 day ago - Revolution Medicines Awarded Voucher for Daraxonrasib (RMC-6236) Under FDA Commissioner's National Priority Voucher Pilot Program - GlobeNewsWire
- 18 days ago - Revolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development Officer - GlobeNewsWire
- 5 weeks ago - Analysts Raise Price Targets Following Strong Data From Revolution Medicines' Pancreatic Cancer Drug - Benzinga
- 5 weeks ago - Revolution Medicines: Shares Soar On Pancreatic Cancer Study Win - I'm Sold - Seeking Alpha
- 5 weeks ago - Revolution Medicines, Inc. (RVMD) Discussion On Metastatic Pancreatic Cancer Update Call (Transcript) - Seeking Alpha
- 5 weeks ago - Revolution Medicines Shares New Clinical Results Supporting Initiation of RASolute 303, a Global Phase 3 Registrational Trial of Daraxonrasib in First Line Metastatic Pancreatic Ductal Adenocarcinoma - GlobeNewsWire
- 2 months ago - Revolution Medicines, Inc. (RVMD) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress - GlobeNewsWire